PDF(Pubmed)
Abstract：
UNASSIGNED: Despite widely disseminated guidelines, pneumococcal and influenza vaccination coverage (VC) remains insufficient in patients with cancer receiving cancer treatment. We performed an interventional study to evaluate VC in patients with cancer treated at the medical oncology departments of three North-of-France hospitals and to assess the effect of medical staff training on VC in these patients.
UNASSIGNED: A standardized questionnaire assessed VC in adult patients with cancer receiving anticancer treatment at three day hospitals during December 2-7, 2019. Subsequently (January 2020), we organized educational training sessions for medical staff from each hospital to discuss the current vaccination guidelines. To assess the impact of training on pneumococcal and influenza VC, we re-administered the same questionnaire in March 2020. Because there are no specific guidelines on Diphtheria-Tetanus-Pertussis (DTP) vaccination and no improvement was expected, DTP VC acted as an internal control.
UNASSIGNED: In total, 272 patients from all three hospitals were enrolled in the \"before study\"; 156 patients from only two hospitals were enrolled in the \"after study\" as medical training and data collection at the third were impossible because of administrative reasons and COVID-19 pandemic. The predictors were age for DTP VC; treatment center for pneumococcal VC; and age, sex, and tumor histology (adenocarcinoma vs. others) for influenza VC. Neither influenza VC (42.6% vs. 55.1%, p = 0.08), nor pneumococcal VC were significantly improved post-intervention (11.8% vs. 15.4%, p = 1). There seems to be a small effect in the most fragile for influenza VC.
UNASSIGNED: As expected, VC was very low in patients with cancer, consistent with the literature. There was no impact of the intervention for pneumococcal and influenza VC.
UNASSIGNED: A standardized questionnaire assessed VC in adult patients with cancer receiving anticancer treatment at three day hospitals during December 2-7, 2019. Subsequently (January 2020), we organized educational training sessions for medical staff from each hospital to discuss the current vaccination guidelines. To assess the impact of training on pneumococcal and influenza VC, we re-administered the same questionnaire in March 2020. Because there are no specific guidelines on Diphtheria-Tetanus-Pertussis (DTP) vaccination and no improvement was expected, DTP VC acted as an internal control.
UNASSIGNED: In total, 272 patients from all three hospitals were enrolled in the \"before study\"; 156 patients from only two hospitals were enrolled in the \"after study\" as medical training and data collection at the third were impossible because of administrative reasons and COVID-19 pandemic. The predictors were age for DTP VC; treatment center for pneumococcal VC; and age, sex, and tumor histology (adenocarcinoma vs. others) for influenza VC. Neither influenza VC (42.6% vs. 55.1%, p = 0.08), nor pneumococcal VC were significantly improved post-intervention (11.8% vs. 15.4%, p = 1). There seems to be a small effect in the most fragile for influenza VC.
UNASSIGNED: As expected, VC was very low in patients with cancer, consistent with the literature. There was no impact of the intervention for pneumococcal and influenza VC.
摘要：
未经评估：尽管准则广为传播，在接受癌症治疗的癌症患者中,肺炎球菌和流感疫苗接种覆盖率(VC)仍然不足.我们进行了一项介入性研究，以评估在法国北部三家医院的肿瘤科接受治疗的癌症患者的VC，并评估这些患者的医务人员培训对VC的影响。
UNASSIGNED：一项标准化问卷评估了2019年12月2日至7日在三天医院接受抗癌治疗的成年癌症患者的VC。随后（2020年1月），我们为每家医院的医务人员组织了教育培训课程，讨论当前的疫苗接种指南。评估培训对肺炎球菌和流感VC的影响，我们在2020年3月重新发放了同样的问卷。因为没有关于白喉-破伤风-百日咳（DTP）疫苗接种的具体指南，并且没有预期的改善，DTPVC充当内部控制。
未经批准：总共，来自所有三家医院的272名患者被纳入“研究前”；仅来自两家医院的156名患者被纳入“研究后”，因为由于行政原因和COVID-19大流行，第三家医院的医疗培训和数据收集是不可能的。预测因素是DTPVC的年龄；肺炎球菌VC治疗中心；和年龄，性别,和肿瘤组织学(腺癌与其他)用于流感VC。两者都不是流感VC（42.6%与55.1%,p=0.08),无肺炎球菌性VC在干预后显著改善(11.8%vs.15.4%,p=1)。对于最脆弱的流感VC似乎有很小的影响。
未经评估：如预期，癌症患者的VC非常低，与文献一致。对肺炎球菌和流感VC的干预没有影响。
UNASSIGNED：一项标准化问卷评估了2019年12月2日至7日在三天医院接受抗癌治疗的成年癌症患者的VC。随后（2020年1月），我们为每家医院的医务人员组织了教育培训课程，讨论当前的疫苗接种指南。评估培训对肺炎球菌和流感VC的影响，我们在2020年3月重新发放了同样的问卷。因为没有关于白喉-破伤风-百日咳（DTP）疫苗接种的具体指南，并且没有预期的改善，DTPVC充当内部控制。
未经批准：总共，来自所有三家医院的272名患者被纳入“研究前”；仅来自两家医院的156名患者被纳入“研究后”，因为由于行政原因和COVID-19大流行，第三家医院的医疗培训和数据收集是不可能的。预测因素是DTPVC的年龄；肺炎球菌VC治疗中心；和年龄，性别,和肿瘤组织学(腺癌与其他)用于流感VC。两者都不是流感VC（42.6%与55.1%,p=0.08),无肺炎球菌性VC在干预后显著改善(11.8%vs.15.4%,p=1)。对于最脆弱的流感VC似乎有很小的影响。
未经评估：如预期，癌症患者的VC非常低，与文献一致。对肺炎球菌和流感VC的干预没有影响。
